Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan.
Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Japan.
Intern Med. 2021 Apr 1;60(7):1011-1017. doi: 10.2169/internalmedicine.5893-20. Epub 2020 Nov 9.
A durable response after the discontinuation of immune checkpoint-inhibitor therapy has previously been reported in several cancers. We herein describe a patient with gastric cancer who maintained a durable response after the discontinuation of nivolumab. A 65-year-old man was treated with nivolumab as a sixth-line therapy for recurrent gastric cancer. After four cycles of nivolumab therapy, he showed a partial response. But the treatment was discontinued when two immune-related adverse events occurred after six cycles. Disease regression was sustained for approximately 2 years, without the re-administration of nivolumab. The characteristics leading to such responses are unclear, and further studies are warranted in this regard.
先前已有报道称，在几种癌症中，免疫检查点抑制剂治疗停药后仍能持续产生应答。我们在此描述了一例接受纳武利尤单抗治疗后停药仍能持久应答的胃癌患者。一名 65 岁男性因复发性胃癌接受纳武利尤单抗作为第六线治疗。接受纳武利尤单抗治疗四个周期后，他出现部分缓解。但在六个周期后发生两次免疫相关不良事件后，停止了治疗。疾病缓解持续了大约 2 年，没有重新使用纳武利尤单抗。导致这种应答的特征尚不清楚，在这方面需要进一步的研究。
Zotero 插件
